Lori Kolb
Family · Pennsburg, PANPI 1467929729
Payments from drug & device makers
Across 45 payments — averaging $20.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$113
- Biohaven Pharmaceuticals, Inc.$86
- Bristol Myers Squibb$79
- UCB, Inc.$61
- Amgen$58
- Novartis$56
- plus $448 from 15 others
What the payments were for
- Food & beverage$900100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 6 | $113 |
| Biohaven Pharmaceuticals, Inc. | 4 | $86 |
| Bristol Myers Squibb | 4 | $79 |
| UCB, Inc. | 3 | $61 |
| Amgen | 2 | $58 |
| Novartis | 3 | $56 |
| CSL Behring | 2 | $48 |
| Eisai Inc. | 2 | $41 |
| Neurelis, Inc. | 2 | $40 |
| Supernus Pharmaceuticals, Inc. | 2 | $39 |
| Upsher-smith Laboratories LLC | 2 | $39 |
| Sanofi | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
| Lilly USA, LLC | 1 | $25 |
| AstraZeneca | 1 | $25 |
| Lundbeck LLC | 1 | $24 |
| Amneal Pharmaceuticals LLC | 2 | $24 |
| Acadia Pharmaceuticals Inc | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$900 in reported general payments places this provider in the 70th percentile of 4,717 family providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lorazepam | 99 | $795 |
| Morphine Sulfate | 26 | $424 |
| Oxycodone Hcl | 26 | $286 |
| Tramadol Hcl | 13 | $145 |
Paid to pharmacies, not to this prescriber.
Other family in Pennsburg
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Jessica LindenbergerPittsburgh$131K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.